Agree
. Update is due. Plenty of cash.
NSB is working with a highly experienced and qualified regulatory consultancy that holdsoffices in UK, EU, US and Australia, to ensure that NSB can gain as much insight from the FDAand confirm that the development plan in place for EmtinB within Ophthalmology is withinthe regulator's expectations to allow the initiation of a clinical trial.It is expected that this submission will occur in Q1 2024.
EmtinB™ Early Phase Clinical StudyThe Company’s Early Phase Clinical Study data is locked and is awaiting a finalised statisticalreport from its collaborator to allow for a thorough process of interpretation and reporting.The interpretation of this data is expected in Q1 2024.
IMO
Ann: NSB Receives A$2.2M Research & Development Tax Refund, page-3
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.507M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.5¢ | $1.564K | 34.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2221 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 8000 | 1 |
View Market Depth
| Last trade - 14.18pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.5¢ |
Change
0.000 ( 2.17 %) |
||||
| Open | High | Low | Volume | ||
| 4.5¢ | 4.5¢ | 4.5¢ | 37221 | ||
| Last updated 14.18pm 10/05/2024 ? | |||||
| NSB (ASX) Chart |